uniQure looks beyond Glybera

uniQure N.V. (NASDAQ:QURE) has shifted its attention from Glybera alipogene tiparvovec to new gene therapy candidates in its pipeline.

On Thursday, the company said FDA has required an additional trial of Glybera to support a potential BLA submission to treat lipoprotein lipase ( LPL) deficiency, and CEO Jorn Aldag told BioCentury the company has "moved on from Glybera. There are other milestones ahead." ...